GlassScriptPhysician profile
Rachel L Mitchell
NPI 1992091995
$6,355.74
in general payments reported to CMS, 2019-2025
54 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $677 · 2021: $244 · 2022: $795 · 2023: $935 · 2024: $648 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $670.17 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Novartis Pharmaceuticals Corporation | $608.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $565.72 | 2019-2025 | Lynparza, Tagrisso, Calquence |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Genzyme Corporation | $291.56 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $271.63 | 2019-2024 | Opdualag, Augtyro, Opdivo |
| Janssen Biotech, INC. | $264.32 | 2019-2023 | Imbruvica, Darzalex |
| Daiichi Sankyo INC. | $263.65 | 2022-2025 | Enhertu |
| Pfizer INC. | $207.72 | 2019-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $166.53 | 2019-2020 | |
| Kerecis Limited | $156.00 | 2020-2021 | |
| Integra Lifesciences Corporation | $153.35 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Karyopharm Therapeutics INC. | $143.62 | 2022-2023 | Xpovio |
| Celgene Corporation | $142.65 | 2019-2024 | Pomalyst, Reblozyl |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.